Citation Tools

Original research
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Download to a citation manager

Cite this article as:
Zakharia Y, McWilliams RR, Rixe O, et al
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma